Company Filing History:
Years Active: 1999-2001
Title: Innovations by Jennifer J Moore
Introduction
Jennifer J Moore is a notable inventor based in Chicago, IL, who has made significant contributions to the field of molecular diagnostics. With a total of three patents to her name, she has focused her research on developing innovative solutions for detecting oncogenic viruses.
Latest Patents
One of her latest patents includes the development of nucleic acid primers and probes for detecting oncogenic human papillomaviruses (HPV). This patent provides probe sequences that are useful for identifying various oncogenic HPV types, including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. These sequences can be utilized in hybridization assays or amplification-based assays designed to detect the presence of these oncogenic HPV types in test samples. Additionally, these sequences can be offered as part of a diagnostic kit. Another significant patent involves nucleic acid primers and probes for detecting HIV-1 and HIV-2. This patent provides primer/probe sets that are effective for detecting either or both HIV types in test samples. The primer/probe sets can be employed in nucleic acid amplification procedures, including PCR or RT-PCR, and can also be packaged in kits with other reagents for conducting nucleic acid amplification reactions.
Career Highlights
Jennifer is currently associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. Her work at Abbott has allowed her to contribute to advancements in diagnostic technologies, particularly in the detection of viral infections.
Collaborations
Throughout her career, Jennifer has collaborated with esteemed colleagues, including Paul E Kroeger and Klara Abravaya. These collaborations have further enhanced her research and development efforts in the field of molecular diagnostics.
Conclusion
Jennifer J Moore's innovative work in developing diagnostic tools for detecting oncogenic viruses has made a significant impact in the healthcare industry. Her contributions continue to advance the field of molecular diagnostics and improve patient outcomes.